Recent Approaches of Antibody Therapeutics in Androgenetic Alopecia

Therapeutic antibodies (Abs) are emerging as promising alternatives to traditional treatments like minoxidil and finasteride for androgenetic alopecia (AGA), offering benefits such as longer half-lives and reduced administration frequency. Direct injection into hair loss areas could enhance efficacy and reduce systemic side effects. However, the development of Abs for AGA is challenging due to the need for androgen responsiveness and presence in the extracellular fluid or cell surface around hair follicles. Recent progress includes targeting the prolactin receptor, Interleukin-6 receptor, C-X-C motif chemokine ligand 12, and dickkopf 1, but these therapies are still in early stages and require further validation and optimization for clinical use.